Xilio Therapeutics XLO Stock
Xilio Therapeutics Price Chart
Xilio Therapeutics XLO Financial and Trading Overview
| Xilio Therapeutics stock price | 8.9 USD |
| Previous Close | 8.79 USD |
| Open | 8.99 USD |
| Bid | 6.47 USD x 200 |
| Ask | 11.5 USD x 200 |
| Day's Range | 8.83 - 9.07 USD |
| 52 Week Range | 6.47 - 12.74 USD |
| Volume | 26.14K USD |
| Avg. Volume | 44.3K USD |
| Market Cap | 58.78M USD |
| Beta (5Y Monthly) | -0.093 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.28 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20 USD |
XLO Valuation Measures
| Enterprise Value | -90208416 USD |
| Trailing P/E | N/A |
| Forward P/E | -15.413793 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.0990528 |
| Price/Book (mrq) | 1.1483622 |
| Enterprise Value/Revenue | -1.687 |
| Enterprise Value/EBITDA | 2.208 |
Trading Information
Xilio Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.093 |
| 52-Week Change | -3.24% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 12.74 USD |
| 52 Week Low | 6.47 USD |
| 50-Day Moving Average | 8.24 USD |
| 200-Day Moving Average | 9.19 USD |
XLO Share Statistics
| Avg. Volume (3 month) | 44.3K USD |
| Avg. Daily Volume (10-Days) | 35.72K USD |
| Shares Outstanding | 6.58M |
| Float | 3.65M |
| Short Ratio | 2.63 |
| % Held by Insiders | 28.57% |
| % Held by Institutions | 53.54% |
| Shares Short | 165.27K |
| Short % of Float | 2.80% |
| Short % of Shares Outstanding | 2.51% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -58.52% |
| Operating Margin (ttm) | -111.57% |
| Gross Margin | 79.12% |
| EBITDA Margin | -76.38% |
Management Effectiveness
| Return on Assets (ttm) | -19.76% |
| Return on Equity (ttm) | -75.20% |
Income Statement
| Revenue (ttm) | 53.48M USD |
| Revenue Per Share (ttm) | 9.25 USD |
| Quarterly Revenue Growth (yoy) | 331.70% |
| Gross Profit (ttm) | 42.32M USD |
| EBITDA | -40855000 USD |
| Net Income Avi to Common (ttm) | -31300000 USD |
| Diluted EPS (ttm) | -2.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.33M USD |
| Total Cash Per Share (mrq) | 25.13 USD |
| Total Debt (mrq) | 6.64M USD |
| Total Debt/Equity (mrq) | 9.15 USD |
| Current Ratio (mrq) | 3.59 |
| Book Value Per Share (mrq) | 7.785 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56313000 USD |
| Levered Free Cash Flow (ttm) | -23032876 USD |
Profile of Xilio Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 828 Winter Street |
| ZIP | 02451 |
| Phone | 857 524 2466 |
| Website | https://xiliotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 76 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Q&A For Xilio Therapeutics Stock
What is a current XLO stock price?
Xilio Therapeutics XLO stock price today per share is 8.9 USD.
How to purchase Xilio Therapeutics stock?
You can buy XLO shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xilio Therapeutics?
The stock symbol or ticker of Xilio Therapeutics is XLO.
Which industry does the Xilio Therapeutics company belong to?
The Xilio Therapeutics industry is Biotechnology.
How many shares does Xilio Therapeutics have in circulation?
The max supply of Xilio Therapeutics shares is 6.58M.
What is Xilio Therapeutics Price to Earnings Ratio (PE Ratio)?
Xilio Therapeutics PE Ratio is now.
What was Xilio Therapeutics earnings per share over the trailing 12 months (TTM)?
Xilio Therapeutics EPS is -2.28 USD over the trailing 12 months.
Which sector does the Xilio Therapeutics company belong to?
The Xilio Therapeutics sector is Healthcare.
Xilio Therapeutics XLO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}